text_1: Britain backs GSK's gene therapy for 'bubble boy' syndrome.
text_2: GlaxoSmithKline’s gene therapy for the so-called “bubble boy” disease was approved by Britain’s healthcare cost watchdog NICE, despite a price tag of almost 600,000 euros ($700,000).